Qiagen Deal to make Genetic Diagnostic Test for Lung Cancer

15/04/2016 - 3 minutes

Qiagen and Mirati will collaborate on the development of a companion diagnostic for a specific type of form of Non-Small Lung Cancer – supporting Mirati’s new therapy.

mirati_qiagen_diagnostic_mrna_lung_cancerWith its operational headquarters near Düsseldorf (Germany), Qiagen is an EU giant in Molecular Diagnostics, and even stepped into the NGS battleground after the acquisition of an important supplier.

Qiagen is now entering a new collaboration with Mirati Therapeutics (San Diego, US) to create a diagnostic test that would support the eventual commercialization of Mirati’s glesatinib (MGCD265) for Non-small cell lung cancer (NSCLC).

Glesatinib is currently in phase II trials for NSCLC. It’s a tyrosine kinase inhibitor (TKI), a broad type of cancer therapy (common but not infallible). It targets cancer growth by blocking cellular signals from growth factors.

Mirati’s therapy targets two specific proteins: MET (a receptor of a hepatic growth factor) and Axl (a tyrosine kinase receptor). 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member